Is Visepegenatide legal in Australia?

A published phase 3 in 273 treatment-naive Chinese adults cut glycated haemoglobin 1.36 percentage points against 0.63 on placebo at 24 weeks, and it needs no dose titration. In its phase 1 study 28 percent of healthy volunteers developed antidrug antibodies.

Visepegenatide is exenatide with a polyethylene glycol chain attached, which turns a twice-daily injection into a once-weekly one. It comes from PegBio in Hangzhou and carried the development code PB-119 through most of its published literature.

Mechanism: Exenatide, a synthetic version of exendin-4 from Gila monster venom that acts as a GLP-1 receptor agonist, covalently modified with polyethylene glycol. The PEG chain increases hydrodynamic radius and slows renal clearance, extending half-life from the few hours of native exenatide to around 55 hours, which supports weekly dosing at a fixed dose.

Regulatory history: Not approved in the United States. Reported approved in China in November 2025 after the published phase 3; this site has not resolved a Chinese regulatory document, so treat the approval date as reported rather than as verified here.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Visepegenatide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.